Home » Stocks » Regulus Therapeutics

Regulus Therapeutics Inc. (RGLS)

Stock Price: $0.716 USD 0.006 (0.83%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $0.730 +0.014 (1.97%) Aug 10, 7:31 PM

Stock Price Chart

Key Info

Market Cap 19.77M
Revenue (ttm) 60,000
Net Income (ttm) -21.27M
Shares Out 27.61M
EPS (ttm) -1.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $0.716
Previous Close $0.710
Change ($) 0.006
Change (%) 0.83%
Day's Open 0.710
Day's Range 0.683 - 0.750
Day's Volume 1,225,405
52-Week Range 0.430 - 1.740

More Stats

Market Cap 19.77M
Enterprise Value 6.35M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.61M
Float 16.45M
EPS (basic) -1.03
EPS (diluted) -1.03
FCF / Share -0.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 246,300
Short Ratio 0.33
Short % of Float 2.96%
Beta 2.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 329.42
PB Ratio 1.41
Revenue 60,000
Operating Income -19.63M
Net Income -21.27M
Free Cash Flow -21.45M
Net Cash 13.42M
Net Cash / Share 0.49
Gross Margin -9,195.00%
Operating Margin -32,718.33%
Profit Margin -35,448.30%
FCF Margin -35,756.67%
ROA -44.71%
ROE -481.58%
ROIC -3,340.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 1
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$1.00*
(39.68% upside)
Low
0.50
Current: $0.716
High
1.50
Target: 1.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue6.830.070.071.1920.767.6719.5712.7013.798.60
Revenue Growth9388.89%0%-93.97%-94.25%170.69%-60.81%54.09%-7.9%60.32%-
Gross Profit6.830.070.071.1920.767.6719.5712.7013.798.60
Operating Income-16.83-46.76-70.13-81.50-54.76-44.91-17.80-12.57-7.14-15.50
Net Income-18.59-48.71-71.91-81.84-55.75-56.68-18.67-17.41-7.60-15.56
Shares Outstanding17.268.726.274.404.283.673.210.680.01-
Earnings Per Share-1.08-5.59-11.47-18.59-12.96-15.48-5.88-25.44-1,029.88-
Operating Cash Flow-19.82-43.27-58.77-56.88-49.86-39.51-28.33-8.72-15.0612.31
Capital Expenditures0.10-0.02-0.30-0.91-1.36-1.15-0.80-1.15-0.47-1.88
Free Cash Flow-19.72-43.30-59.08-57.80-51.22-40.66-29.13-9.87-15.5310.42
Cash & Equivalents34.1213.9460.0776.1111516011498.1038.140.00
Total Debt14.6316.5819.8619.80-23.4011.2810.1310.00-
Net Cash / Debt19.49-2.6440.2256.3111513610387.9728.140.00
Assets42.0827.9377.8110114117112310442.88-
Liabilities22.0733.7842.5944.5917.0139.4729.6141.4341.68-
Book Value20.02-5.8535.2256.0812413293.4662.09-41.49-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Regulus Therapeutics Inc.
Country United States
Employees 21
CEO Joseph P. Hagan

Stock Information

Ticker Symbol RGLS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RGLS
IPO Date October 4, 2012

Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.